Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour
| État | Nombre total | Résumé |
|---|---|---|
| En négociation | 39 | Non liées à l’oncologie : 22 Liées à l’oncologie : 17 |
| Négociations envisagées | 21 | Non liées à l’oncologie : 11 Liées à l’oncologie : 10 |
| Négociations terminées | 896 | Avec lettre d’intention : 774 Sans entente : 122 |
| Négociations qui n’ont pas eu lieu | 113 |
Activités de l’APP dans les quatre dernières semaines
Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.
Lettres d’engagement transmises au cours des quatre dernières semaines
| Marque | Fabricant | Indication | Date d’engagement |
|---|---|---|---|
| Epuris | Cipher | Acne Vulgaris | |
| Perjeta | Hoffmann-La Roche Ltd. | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer | |
| Rebyota | Ferring Canada Inc. | Clostridioides difficile infection, prevention | |
| Lyvdelzi | Gilead Sciences Canada Inc. | For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. | |
| Quviviq | Idorsia Pharmaceuticals Canada Ltd. | Insomnia | |
| Alyftrek | Vertex Pharmaceuticals (Canada) Incorporated | Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older | |
| Ranvu | Apotex Inc. | Multiple Indications | |
| Carvykti | Janssen Inc. | For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide. | |
| Carvykti | Janssen Inc. | (du) Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment | |
| Calquence | AstraZeneca Canada Inc. | Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL. | |
| Venclexta | AbbVie Corporation | Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) | |
| Verzenio | Eli Lilly Canada Inc. | For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy. | |
| Verzenio | Eli Lilly Canada Inc. | For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disea | |
| Talvey | Janssen Inc. | For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrat |